The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model
Amy L Inselman,Elysia A Masters,Jalina N Moore,Rajiv Agarwal,Audrey Gassman,Gemma Kuijpers,Richard D Beger,Kenneth B Delclos,Sybil Swift,Luísa Camacho,Michelle M Vanlandingham,Daniel Sloper,Noriko Nakamura,Gonçalo Gamboa da Costa,Kellie Woodling,Matthew Bryant,Raul Trbojevich,Qiangen Wu,Florence McLellen,Donna Christner
DOI: https://doi.org/10.3389/fphar.2024.1365151
2024-04-16
Abstract:Preparations of black cohosh extract are sold as dietary supplements marketed to relieve the vasomotor symptoms of menopause, and some studies suggest it may protect against postmenopausal bone loss. Postmenopausal women are also frequently prescribed bisphosphonates, such as risedronate, to prevent osteoporotic bone loss. However, the pharmacodynamic interactions between these compounds when taken together is not known. To investigate possible interactions, 6-month-old, female Sprague-Dawley rats underwent bilateral ovariectomy or sham surgery and were treated for 24 weeks with either vehicle, ethinyl estradiol, risedronate, black cohosh extract or coadministration of risedronate and black cohosh extract, at low or high doses. Bone mineral density (BMD) of the femur, tibia, and lumbar vertebrae was then measured by dual-energy X-ray absorptiometry (DEXA) at weeks 0, 8, 16, and 24. A high dose of risedronate significantly increased BMD of the femur and vertebrae, while black cohosh extract had no significant effect on BMD individually and minimal effects upon coadministration with risedronate. Under these experimental conditions, black cohosh extract alone had no effect on BMD, nor did it negatively impact the BMD-enhancing properties of risedronate.